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Abstract
Background and Aims—Fatigue is the most frequent and often debilitating symptom of
chronic hepatitis C. It is unclear whether successful therapy of hepatitis C leads to its clinical
improvement. In the Virahep-C study, patients with hepatitis C virus (HCV) genotype 1 infection
were treated with peginterferon alfa-2a and ribavirin for up to 48 weeks while undergoing
assessment of viral kinetics and clinical symptoms.
Methods—Fatigue measurements were conducted, before, during and after therapy, as `presence'
(yes/no) and `severity' (visual analogue scale: 0 to 100mm). The clinical, histologic and virologic
features that correlated with the presence and degree of fatigue were assessed focusing upon
changes associated with sustained virological response (SVR).
Results—At baseline, 52% (n= 401) participants reported having fatigue, which was more
common in women than men (59% vs. 48%, p=0.02) and slightly more severe (30 vs. 22mm,
p=0.056). Fatigue was frequent and worse in cirrhotics versus those with lesser fibrosis (66% vs.
49%; 34 vs. 24mm). Fatigue did not correlate with other parameters. The proportion of patients
and median fatigue scores increased on treatment (52% to 78%; 25 to 40mm, p<0.0001) with
higher fatigue noted amongst those who ultimately achieved SVR (p<0.0001). On achieving SVR,
there was a significant decrease in both frequency and severity of fatigue compared to their
baseline (53% to 33%; 27 to 13mm, both p<0.0001).
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Conclusion—Fatigue is common in patients with chronic hepatitis C but associated poorly with
biochemical parameters. Sustained response is accompanied by substantial improvement of
fatigue.
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Introduction
Fatigue is the most frequent symptom of liver disease and has a major effect on quality of
life and daily activity in patients chronically infected with hepatitis C virus (HCV) [1–6].
However, the degree of fatigue varies considerably among patients and often correlates
poorly with the severity of disease. In many instances, it is unclear whether fatigue is caused
by hepatitis C and, if so, whether it is due to the chronic viral infection or to the degree of
liver inflammation, injury or dysfunction [2, 3, 7]. A better understanding of the nature of
fatigue in liver disease is hampered by (1) the fact that it is a subjective experience and
difficult to measure and quantify; (2) is often multifactorial; and (3) its quality and severity
are similar among the different etiologies.
Many clinical trials in liver disease have tried to capture the effects of medical treatments on
fatigue using self-report instruments, with variable success [2, 3, 8–12]. Estimating the
presence and severity of fatigue is particularly important in studies of interferon-based
therapies for hepatitis C [7]. Even with recent advances in treatment for this disease,
regimens still include peginterferon, administered for 24 to 48 weeks, based upon viral
genotype and viral response [13–16]. During interferon therapy, fatigue is the most common
side effect and can lead to early termination of therapy and treatment failure [7, 17, 18].
Perhaps just as important as capturing the degree of fatigue that occurs during therapy, is
whether eradication of HCV ultimately leads to improvement in symptoms. While several
studies have evaluated and noted improvements in quality of life (QoL) with successful
therapy [18–20], the typical QoL construct can be diffuse, encompassing mental, physical,
social, occupational and role functioning, without a detailed analysis of changes in specific
symptoms. While the rationale for interferon treatment is usually to prevent long-term
complications of hepatitis C, another reason is to improve clinical symptoms and quality of
life.
The data from the Viral Resistance to Antiviral Therapy of Hepatitis C (Virahep-C) study
offered a unique opportunity to evaluate the effect of therapy on fatigue in hepatitis C
patients. Virahep-C enrolled 401 African-Americans (AAs) and Caucasian Americans
(CAs), with HCV genotype 1 who were treated with peginterferon and ribavirin for up to 48
weeks while undergoing careful and extensive longitudinal evaluation of clinical,
biochemical, virologic, immunologic factors and clinical symptoms [21–24], including
fatigue. Fatigue severity was measured using a visual analogue scale (VAS), which is easy
to administer, understand and not restricted by literacy levels [25, 26]. Notably, VASs have
been used in multiple clinical contexts to study fatigue, including liver diseases [27–31], and
are highly correlated with other validated fatigue measurements [25, 28, 31, 32]. The aim of
this study was to assess whether fatigue was associated with disease severity and whether
fatigue improved with successful treatment.
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The Virahep-C study design
Virahep-C was a prospective clinical study conducted at 8 U.S. medical centers between
2002 and 2005 in which 196 AAs and 205 CAs patients with chronic hepatitis C, genotype
1, were treated with the standard antiviral regimen of peginterferon alfa-2a (Pegasus, Roche
Pharmaceuticals; Nutley, NJ) and ribavirin (Copegus, Roche) while undergoing extensive
studies of HCV viral kinetics, immune function, genetics and interferon signaling pathways
[21–24, 33]. The major aims of Virahep-C were to define response rates to conventional
therapy among AA versus CA patients and investigate factors associated with nonresponse
in the two racial groups. Details of Virahep-C are described elsewhere [21]. All patients
provided fully informed written consent and the study design and all details were approved
by local Institutional Review Boards.
Patients were evaluated and had blood tests taken twice before therapy (Screening Visits 1
and 2), at treatment weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 36, 40, 44 and 48, and 4, 12 and 24
weeks after treatment discontinuation. Patients completed symptom questionnaires and were
asked about side effects at Screen 2 and at all the treatment and the follow-up weeks. Blood
samples were taken for routine liver tests (including serum alanine and aspartate
aminotransferase levels: ALT, AST), blood counts and HCV RNA concentrations, which
were measured centrally using an assay with a lower limit of sensitivity of 500 IU/mL
(COBAS Amplicor Hepatitis C Virus Monitor Test, version 2.0 assay: Roche Molecular
Diagnostics, Alameda CA).
Patients who remained HCV RNA positive after 24 weeks of therapy stopped treatment and
were considered non-responders (NR) whereas those who were HCV RNA negative at week
24 (responders) continued treatment for a total of 48 weeks. Patients who remained HCV
RNA negative for at least 24 weeks after treatment were considered to have a sustained
virological response (SVR), while those who had rebound of HCV RNA positivity were
considered to have had a relapse (if it occurred after treatment) or breakthrough (if while on
treatment). For the current analyses, the major focus was on the responder versus the non-
responder populations and especially those who achieved SVR.
Assessment of `presence' of fatigue (`fatigue presence')
The presence or absence of fatigue was assessed directly by study personnel (usually a
research nurse coordinator) asking, “Do you have fatigue?” Patients were asked to respond
“Yes” or “No.”
Assessment of `severity' of fatigue (`fatigue severity')
A VAS for fatigue was administered at each clinic visit (Supplement figure 3). The scales
were displayed on a computer screen and patients were asked to touch a point along a 10 cm
line between “None” and “Worst ever”, the position of which best reflected how much
fatigue they had experienced during the previous week. The results were sent directly to the
Data Coordinating Center, and study personnel were masked to patient responses. The
degree of fatigue was scored from 0 to 100 mm by measuring from the start of the line to the
patient mark.
Depression was also measured at each clinic visit using a VAS (Depression VAS). Analyses
of depression during Virahep-C have been published [33].
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The prevalence of fatigue at baseline by categorical patient characteristics was summarized
using frequency and percent and the associated p-values were obtained from univariate
logistic regression. Fatigue severity was summarized using median and quartiles. Due to its
non-normality, fatigue severity between two groups was compared using Wilcoxon rank-
sum test and across multiple groups using Kruskal-Wallis test. Univariate and multivariate
logistic regression was used in assessing the association between incidence of fatigue
(binary) and patient characteristics. Wilcoxon rank sum test was used in assessing the
association between fatigue presence (non-normal) and patient characteristics; signed rank
test was used to assess significant changes in fatigue presence between any two time points.
All analyses were conducted using SAS 9.3 (SAS Institute Inc., Carey, NC).
Results
Baseline Results
At the time of screening, 207 of 401 (52%) study participants reported the presence of
fatigue (Table 1). Fatigue was more common among women (59%) than men (48%) (p=
0.02). There were no statistically significant differences in the presence of fatigue by age,
race, body mass index (BMI), ALT or AST level, viral subtype (1a vs. 1b), HCV RNA
concentration, or any other baseline variable (Table 1). Liver histology taken within one
year before enrollment was available from 399 patients and the presence of fatigue did not
vary by inflammatory scores, but was more common in patients with cirrhosis (Ishak
fibrosis score 5–6: 66%) than those with minimal (Ishak 0–2: 49%) or moderate fibrosis
(Ishak 3–4: 53%) although not statistically significant (p=0.25). Multivariable logistic
regression analysis at screening showed that no variables, except gender, to have a
significant association with the presence of fatigue.
The severity of fatigue was measured at baseline by the fatigue VAS (n=390), and the
median fatigue VAS score was 25 mm. Of 390, 205 patients (53%) reported having fatigue,
of which 181 (88%) patients marked a score of greater than 10 mm on the fatigue severity
VAS. Fatigue severity was slightly higher for women than men (median 30 vs. 22 mm:
p=0.056) (Table 2). Baseline fatigue severity was similar between AA and CA patients, and
did not vary consistently by BMI, HCV RNA levels or histological inflammatory scores.
Again noted was fatigue severity higher among patients with cirrhosis than in those with
minimal or moderate fibrosis (median 34 vs. 24 and 25 mm), although not statistically
significant (p= 0.62). Interestingly, fatigue severity was worse among patients with normal
ALT levels (< 40 U/L: 37 mm) than in those with mild (40–100 U/L: 25 mm) or moderate-
to-high ALT elevations (>100 U/L: 21 mm) (p= 0.02). In contrast, fatigue scores did not
vary by AST levels. In multivariable analysis at screening, controlling for sex, race, baseline
viral level and Ishak score, younger age and lower ALT was associated with more severe
fatigue (p<0.05 for both).
To better classify fatigue severity, fatigue VAS scores (n=390) were grouped into three
categories: no or minimal fatigue (0 to 10 mm: n =120), mild-to-moderate fatigue (>10 to 40
mm: n=115) and severe fatigue (>40 to 100 mm: n= 155). The clinical, demographic,
biochemical and histologic features of patients with these three degrees of fatigue are
tabulated in Table 2. Those with cirrhosis had significantly higher proportion with severe
fatigue compared to those with lesser degree of fibrosis (48% vs. 38%: p-value=0.005).
On Treatment Results
During treatment, the proportion of patients who admitted to having fatigue increased from
52% at baseline to 78% at week 4 (p<0.0001), and remained at this level for the duration of
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treatment (range: 67% to 79%) (Figure 1a). The median fatigue severity score increased
during the first 4 weeks of therapy (from 25 to 40 mm, p<0.0001) and remained at this
higher level for the duration of treatment (range: 29 to 43 mm).
Patterns of changes in fatigue severity on treatment were assessed in subgroups of patients
during treatment; comparing women vs. men (Supplemental Figure 1), AA vs. CA
participants (Supplemental Figure 2). Fatigue severity was greater amongst women than
men (p<0.001: Supplemental Figure 1) and amongst CA compared to AA patients during
therapy (p<0.001: Supplemental Figure 2). In addition, both the frequency and severity of
fatigue was greater among participants who ultimately achieved SVR vs. NRs (p<0.001:
Figures 2a and 2b, respectively).
After Treatment Results
Once therapy terminated, the proportion of patients who admitted to feeling fatigued
decreased. By 12 weeks after discontinuation, proportions of patients with fatigue were
lower than that at baseline (36% in responders, 42% non-responders vs 52% at baseline,
Figure 1a). The median fatigue VAS scores were also lower (11 mm in responders, 17 mm
in non-responders vs 25 mm at baseline: Figure 1b).
The improvement in fatigue was greater among patients who achieved an SVR than in those
who never became HCV RNA negative (non-responders). Overall, the proportion of SVR
patients who admitted to having fatigue decreased from 53% at baseline to 33% 24 weeks
after treatment (p<0.0001; n=161), and the median VAS fatigue score decreased from 27
mm to 13 mm (p<0.0001; n=158). These changes were especially profound in patients who
at baseline had severe levels of fatigue (fatigue VAS score >40 mm), in whom the median
fatigue VAS score decreased from 64 mm at baseline to 21 mm at follow-up week 24
(p<0.0001, n= 66; Figure 3a). Among non-responders, the presence and severity of fatigue
decreased but not significantly between baseline and 24 weeks after treatment regardless of
the initial score (p>0.05, Figure 3b). Furthermore, there was no significant change in fatigue
presence or severity among patients who had virologic relapse (n= 60) or breakthrough (n=
21) (data not shown).
As expected, fatigue score was associated with depression, (Spearman correlation
coefficients, rs=0.53 at baseline; 0.66 at treatment week 24; and 0.73 at follow-up week 24;
all p < 0.0001). Controlling for the presence of depression did not alter the significance of
the changes in fatigue severity after successful completion of therapy compared to baseline
(p<0.0001).
Discussion
Fatigue is perhaps the most common symptom among patients with chronic hepatitis C and
is a troublesome side effect of its therapy[1, 2, 4, 7, 9, 34, 35]. In this study, half of patients
enrolled in a study of antiviral therapy of HCV admitted to having some degree of fatigue,
of whom two-thirds rated it as moderate or severe. The current literature suggests that the
presence and severity of fatigue correlates poorly with disease activity although it may be
somewhat more common and severe in patients with cirrhosis [1, 9, 19, 36]. In the current
study, the differences in frequency and severity of fatigue in patients with cirrhosis
compared to those with lesser degrees of fibrosis were not statistically significant; however,
the data were limited by numbers of patients with more advanced disease (n=29: 7% of the
cohort) but notable was that more cirrhotics had worse fatigue than those with minimal
fibrosis.
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As expected, fatigue became more troublesome during interferon therapy [9, 14, 15, 18].
Fatigue worsened for the first 4 weeks of therapy, then plateaued, and did not completely
resolve or return to baseline until 12 weeks after stopping therapy. The cause of fatigue
induced from interferon therapy is likely multifactorial, but may include the systemic effects
of cytokines, secondary effects of treatment-related side effects such as anemia [37–40], as
well as the psychosocial stress of having to maintain occupational and family
responsibilities while undergoing medical treatment. Thus, although attributing the cause of
fatigue to a specific set of genes or proteins is an attractive and parsimonious notion, an
interlinked pathway involving multiple genetic, biochemical and environmental processes is
a more realistic probability [41], and an area for future research.
Importantly, the presence and severity of fatigue ultimately declined in patients with
sustained clearance of HCV. The results remained consistent even after controlling for
depression, a common cofounder of fatigue. These findings indicate that therapy of HCV
can result in significant and sustained improvement in clinical symptoms, and that the
measurement of fatigue using VASs is successful in capturing these changes. Improvements
in fatigue were most convincing in patients with moderate to severe levels of fatigue at
baseline. Thus, patients with relatively non-significant biochemical or histologic disease, but
who have troublesome symptoms such as fatigue, should be considered for antiviral therapy.
The likely cause for the improvement of fatigue with eradication of HCV is unclear. It is
also unclear if certain aspects of fatigue (i.e., physical, mental or cognitive) fare better, as
the VAS is a quantitative measure rather than a qualitative one. While patients' awareness of
virological response could have a beneficial psychological effect on perceptions of fatigue,
the fatigue assessments were obtained before the results of virological testing were known,
and improvements in fatigue were achieved well before knowledge of SVR was given to
patients.
A few limitations of this study should be noted. The cohort tested was a relatively biased
sample of patients with HCV infection, as these subjects all had genotype 1 and all were
sufficiently motivated to undergo a rigorous, prolonged medical therapy with notable
adverse side effects. Another caveat to consider is that the improvements in fatigue scores
were seen predominantly among patients who had moderate or severe levels of fatigue
before treatment, and there was little or no improvement in patients who reported minimal
fatigue initially. Such findings suggest that there is little room for improvement in fatigue
among those with lower levels at baseline, or that the VAS is not sensitive enough to detect
minor improvements.
In conclusion, use of a simple fatigue VAS demonstrated that at least half of patients with
chronic hepatitis C who participated in a clinical trial had complaints of fatigue at baseline,
however, fatigue significantly improved in those who achieved viral eradication. Further
analyses of the quality of fatigue in chronic liver disease, as well as the biologic and
psychosocial pathways associated with this subjective symptom are needed to improve the
management of chronic liver disease and assessment of the benefits of antiviral therapy,
whether curative or ameliorative in nature.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. `Presence of' and `severity' of fatigue at baseline, on treatment and follow-up of all
patients
(a) Proportion (`yes/no') of patients with fatigue and, (b) the Severity of fatigue (VAS), at
baseline, on treatment and on follow-up. Each point marks the week of patient evaluation
and fatigue measurement: at screening visit 2, treatment weeks 1, 2, 4, 8, 12, 16, 20, 24, 32,
36, 40, 44 and 48 (until week 24 for non-responders), and on follow-up at 4, 12 and 24
weeks after treatment discontinuation. ◻ All patients on treatment, ▵ Responder, ◯ Non-
responders (NR). Solid line, on treatment; and dashed line: off-treatment follow-up weeks.
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Figure 2. `Presence of' and `severity' of fatigue at baseline, on treatment and follow-up amongst
those achieving SVR versus NR
(a) Proportion of patients with fatigue and (b) severity of fatigue amongst those who
achieved sustained virologic response (SVR) versus NR. ▵ SVR (blue line), ◯ NR patients
(red line). Solid line: on treatment, and dashed line: off-treatment, follow-up weeks.
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Figure 3. Severity of fatigue categorized by baseline fatigue status in responders and NR
Severity of fatigue by baseline fatigue status in (a) Responders (b) NR patients. Red line:
none-to-mild fatigue: VAS ≤10; Green line: moderate fatigue: VAS >10 to ≤40 and; Blue
line: severe fatigue: VAS >40. (a) ▵ Responder, (b) ◯ Non-responders. Solid line: on
treatment, and dashed line: off-treatment follow-up weeks.
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Table 1
Presence of fatigue at the time of enrollment by selected clinical, virological and histologic features.
n Fatigue (n, %) p value
Total 401 207 (52%)
Gender:
Male 261 124 (48%) 0.02*
Female 140 83 (59%)
Race:
White 205 113 (55%) 0.15
Black 196 94 (48%)
Age:
<40 years 49 25 (51%)
>40 years 352 182 (51%) 0.93
BMI:
<25 95 46 (48%)
25–30 149 78 (52%) 0.64
>30 150 77 (51%) 0.86
ALT:
<40U/L 68 36 (53%)
40–100U/L 220 116 (53%) 0.77
>100U/L 111 55 (50%) 0.58
AST:
<30U/L 58 30 (52%)
30–100U/L 283 147 (52%) 0.97
>100U/L 58 30 (52%) 0.98
HCV genotype:
1a 210 115 (55%)
1b 148 73 (49%) 0.98
HCV RNA:
>400,000 31 18 (58%)
<400,000 368 188 (51%) 0.46
HAI Score:
1–5 34 17 (50%)
5–10 163 86 (53%) 0.71
11–18 202 103 (51%) 0.95
Fibrosis:
0–2 253 125 (49%)
3–4 117 62 (53%) 0.49
5–6 29 19 (66%) 0.14
*
p<0.05
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